Receive our newsletter – data, insights and analysis delivered to you
September 19, 2011

GI Dynamics’ EndoBarrier shown to improve glycaemic control rate

GI Dynamics' EndoBarrier gastrointestinal liner has demonstrated improvement in glycaemic control and weight loss as part of a trial. Seventeen obese patients with type 2 diabetes were treated with the EndoBarrier for 24 weeks. The levels of HbA1c, glucose, insulin, GLP-1, GI

By cms admin

GI Dynamics’ EndoBarrier gastrointestinal liner has demonstrated improvement in glycaemic control and weight loss as part of a trial.

Seventeen obese patients with type 2 diabetes were treated with the EndoBarrier for 24 weeks.

The levels of HbA1c, glucose, insulin, GLP-1, GIP and PYY were assessed in each placement before and one week after the placement of the EndoBarrier, and before and one week after its removal.

The trial showed that EndoBarrier resulted in increased insulin sensitivity, increased levels of PYY and GLP-1 one-week post-placement, reduction in mean HbA1c levels of 1.4%, normalisation of glucagon response and mean excess weight loss of 29.8%.

Maastricht University Medical Centre, Netherlands, professor Charlotte de Jonge said that the data showed that treatment with the EndoBarrier affects key hormones involved in insulin sensitivity, glucose metabolism and satiety, similar to the impact of gastric bypass, and these changes allow for rapid and sustained improvement in patients with type 2 diabetes.

“In addition, we found that patients maintained diabetic improvements at the end of the follow-up period, one week post-removal. These are important findings in understanding how the EndoBarrier works to treat type 2 diabetes,” de Jonge said.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies

The EndoBarrier has received CE mark approval in Europe for implant periods of up to 12 months of treatment for type 2 diabetes and obesity, and recently received Therapeutic Goods Administration approval in Australia.

GI Dynamics has also received an investigational device exemption approval to begin a pilot clinical trial of the EndoBarrier in the US.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU